- Previous Close
53.76 - Open
53.85 - Bid 54.20 x 800
- Ask 54.28 x 800
- Day's Range
53.41 - 54.29 - 52 Week Range
39.35 - 57.65 - Volume
15,352,875 - Avg. Volume
13,762,076 - Market Cap (intraday)
109.885B - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-3.25 - Earnings Date Oct 31, 2024
- Forward Dividend & Yield 2.40 (4.46%)
- Ex-Dividend Date Oct 4, 2024
- 1y Target Est
52.25
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
www.bms.com34,100
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BMY
View MoreRelated Videos: BMY
Performance Overview: BMY
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BMY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BMY
View MoreValuation Measures
Market Cap
108.99B
Enterprise Value
156.34B
Trailing P/E
--
Forward P/E
7.67
PEG Ratio (5yr expected)
2.07
Price/Sales (ttm)
2.35
Price/Book (mrq)
6.41
Enterprise Value/Revenue
3.36
Enterprise Value/EBITDA
30.36
Financial Highlights
Profitability and Income Statement
Profit Margin
-14.06%
Return on Assets (ttm)
6.00%
Return on Equity (ttm)
-26.59%
Revenue (ttm)
46.51B
Net Income Avi to Common (ttm)
-6.54B
Diluted EPS (ttm)
-3.25
Balance Sheet and Cash Flow
Total Cash (mrq)
6.65B
Total Debt/Equity (mrq)
316.39%
Levered Free Cash Flow (ttm)
15.69B
Research Analysis: BMY
View MoreCompany Insights: BMY
BMY does not have Company Insights
Research Reports: BMY
View MoreBristol's Growing Portfolio and Pipeline Partly Offset Headwinds From Generic Competition
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
RatingPrice TargetOur recent call for a rally in the U.S.
Our recent call for a rally in the U.S. Dollar Index, a reversal in metals, and more struggles in emerging markets took a Mike Tyson left hook to the chin on Tuesday. A "sweeping" stimulus package from China sent Chinese stocks soaring and Materials stocks to the moon. The iShares China Large-Cap ETF (FXI) spiked 10%, its largest one-day move since March 2022, while the iShares MSCI Emerging Markets (EEM) popped 3.4%. The Materials (XLB) sector was the largest gainer on Tuesday, with a 1.4% gain - but that doesn't tell the entire story. The real action took place within the sector, with nonferrous metals and aluminum bolting higher by 7.6%-7.9%. Copper futures spiked 4%, leading to big gains in Southern Copper (SCCO) and Freeport-McMoRan (FCX). Aluminum was led by Norsk Hydro (NHYDY) and Alcoa (AA). Mining stocks also did well, led by BHP Group, Rio Tinto, and MP Materials. Silver futures surged 4.6% and are back at the top of the range that began months ago. The timing of the stimulus package is interesting. Was it in reaction to the Fed's larger-than-expected rate cut and/or an attempt to front-run a possible increase in U.S. tariffs (which would hurt China's competitiveness in certain markets)? We will let others argue about that, as mixing politics with the equity market is like trying to mix oil and water. It generally doesn't work out very well. The bull rages on and now more fuel has been added to the fire. Some are talking about a melt-up. That action is fun while it lasts, but always ends in big losses on the other side. (Mark Arbeter, CMT)
Large Cap US Pick List - September 2024
This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.
Large Cap US Pick List - August 2024
This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.